Background: Ertapenem is a broad-spectrum antibiotic that is increasingly being utilized. Its dosing convenience renders it suitable for outpatient therapy, and its pharmacokinetic characteristics favour its use against complicated urinary tract infections (cUTIs). Despite this, sufficient clinical data are lacking for its use against cUTIs in the outpatient setting. We assessed the microbiological and clinical cure rates associated with ertapenem treatment for cUTIs in two outpatient parenteral antimicrobial therapy (OPAT) departments. Methods: We undertook a prospective observational study of adult patients who received ertapenem for cUTIs between August 2010 and August 2014. Data on patient characteristics, clinical progress and microbiological results were collected and analysed. Results: Sixty-one patients were enrolled. The median age was 59 years (range 24, 83) and 61% were male. The most common diagnoses were pyelonephritis (39%) and prostatitis (15%). The most common causative organism was Escherichia coli (67%). Extended-spectrum β-lactamase (ESBL)-producing organisms were detected in 72% of infections. Microbiological cure was achieved in 67% overall, and was less likely in those with Klebsiella pneumoniae infection (OR = 0. 
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30
Ertapenem has excellent antimicrobial activity against a broad spectrum of pathogens associated with hospital and 
34
Furthermore, its excretion in the urine gives it a favourable pharmacokinetic profile to treat cUTIs [6] . In a well-
35
designed study, ertapenem was found to be as efficacious as ceftriaxone in treating a cohort of cUTIs with non-
36
ESBL producing gram negatives [7] .
37
In the outpatient setting, there are few studies on cohorts of patients with cUTIs caused by ESBL producing gram- whom an informed consent could not be obtained were excluded.
As an observational study the investigators had no input into the duration of treatment. Patients were monitored daily at the OPAT centre. This included clinical assessment for improvement of presenting complaints and days). After completion of treatment, patients were assessed by an infectious diseases physician at 30 days (± 7 56 days) with repeat urinalysis and mid-stream urine culture.
57
The primary outcome of the study was microbiological cure, which was defined as a negative culture on any 58 occasion after treatment. Those with the same organism isolated any time following therapy were considered as 59 persistent infection, and those who developed a new microorganism were considered as having a superinfection,
60
regardless of whether they developed symptoms. The secondary outcome of the study was clinical cure defined as 61 complete resolution of symptoms and signs at diagnosis. Outcome was assessed as therapy success or failure.
62
Failure was defined as developing adverse outcomes in addition to change of therapy, hospital re-admission due to 63 cUTI and mortality.
64
Bacteria were identified by matrix associated laser desorption ionization time of flight mass spectrometry (MALDI-TOF-MS, Bruker Daltoniks GmHB, Bremen, Germany). Antibiotic susceptibility was determined using
66
VITEK II (bioMerieux S.A., Marcy l'Etoile, France), and interpreted using breakpoints according to EUCAST..
67
For descriptive analysis, the means and their standard deviation (SD), or medians with their range were reported.
68
Chi 
Results and data analysis:

75
A total of 61 patients were studied. Baseline demographic features and disease characteristics are summarised in 76 
98
Multivariate logistic regression showed that having an infection with K. pneumoniae at baseline was found to be a 
101
There were no risk factors identified for not achieving clinical cure on univariate analysis, and hence a multivariate 102 analysis was not conducted.
103
The mean duration of therapy for those who achieved microbiological cure was 23.6 days (SD=+/-12.9), and for
104
those who did not was 17.9 days (SD= +/-8.4), but the difference was not significant (p=0.08). Similarly, those 
Discussion
109
In this study, the safety and efficacy of ertapenem in the OPAT setting were demonstrated for the treatment of 110 cUTIs. The overall clinical success rate among patients was 92%, while 3 (5%) patients discontinued therapy due to adverse effects. A total of 52 (85%) had their original organisms eradicated (Table 3) . None of the non-ESBL in those with K. pneumoniae was (50%), and significantly contributed to the overall microbiological cure rate 115 (67%). Of those without microbiological eradication none were re-admitted in the subsequent 3 months for cUTI.
116
Our study was limited by its observational nature and the relatively small number of participants making subgroup 117 analysis difficult. Furthermore, it was a single-arm study with no comparator. The study did not look at outcomes 
125
The largest OPAT cohort prior to our study included 50 patients, but it was in a paediatric population [16] .
126
Similarly, studies conducted in outpatient populations who received ertapenem included even smaller numbers[8-caused by extended-spectrum beta-lactamase-producing bacteria in children. Scand J Infect Dis. 2011; 43: 339- 
